Patents
Literature
2347 results about "Gastroenterology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Gastroenterology is the branch of medicine focused on the digestive system and its disorders. Diseases affecting the gastrointestinal tract, which include the organs from mouth into anus, along the alimentary canal, are the focus of this speciality. Physicians practicing in this field are called gastroenterologists. They have usually completed about eight years of pre-medical and medical education, a year-long internship (if this is not a part of the residency), three years of an internal medicine residency, and two to three years in the gastroenterology fellowship. Gastroenterologists perform a number of diagnostic and therapeutic procedures including colonoscopy, endoscopy, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound and liver biopsy. Some gastroenterology trainees will complete a "fourth-year" (although this is often their seventh year of graduate medical education) in transplant hepatology, advanced endoscopy, inflammatory bowel disease, motility or other topics.
Systems and methods for diagnosis, risk assessment, and / or virtual treatment assessment of visceral ischemia
Systems and methods are disclosed for diagnosis, risk assessment, and / or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel or generating a risk score for risk of disease for the patient's bowel, based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.
Owner:HEARTFLOW INC
Systems and methods for diagnosis, risk assessment, and / or virtual treatment assessment of visceral ischemia
Systems and methods are disclosed for diagnosis, risk assessment, and / or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.
Owner:HEARTFLOW INC
Methods of treatment for cystic fibrosis
This disclosure provides methods of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure also provides pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, and optionally comprising one or more additional CFTR-modulating agents.
Owner:VERTEX PHARMACEUTICALS INC
Systems and methods for analysis of medical images for scoring of inflammatory bowel disease
This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.
Owner:ITERATIVE SCOPES INC
Dosing regimen for treating inflammatory bowel disease
ActiveUS12304956B1Digestive systemPharmaceutical delivery mechanismDosing regimenInflammatory bowel disease
Owner:PARAGON THERAPEUTICS INC
Apparatus and method for an oral nicotine dispensing system
ActiveUS12288439B1Dispensing apparatusCoin-freed apparatus detailsLocking mechanismBiomedical engineering
An apparatus and method for an oral nicotine dispensing system. The apparatus includes storing a plurality of a pods in a magazine within a body, receiving a fingerprint scan from a user via a fingerprint scanner coupled to the body, authenticating the fingerprint scan, de-activating a locking mechanism to allow access to at least a pod upon successful authentication of the fingerprint scan, and dispensing, using at least a drive mechanism, the at least a pod from the magazine through an opening of the body.
Owner:SKYX IP HOLDINGS I LLC
Methods of treating fibrosis
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Owner:ENDEAVOR BIOMEDICINES INC
Methods for treating a fatty liver disease
PCT designated stageWO2025171032A1Digestive systemHeterocyclic compound active ingredientsFatty liverIsopropyl
The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.
Owner:MADRIGAL PHARMACEUTICALS INC
Lactobacillus brevis strain and application of lactobacillus brevis strain in preparation of medicine for preventing or treating hyperuricemia
The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.
Owner:ICDC CHINA CDC
Methods of treating a patient with an inflammatory bowel disease
PCT designated stage expiredWO2025085928A1Microbiological testing/measurementDisease diagnosisUlcerative colitisInflammatory bowel disease
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Owner:ODYSSEY THERAPEUTICS INC
Methods of treating fibrosis
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.
Owner:ENDEAVOR BIOMEDICINES INC
Adiponectin enhancer, oral composition for enhancing adiponectin, and use of plasmalogen
PendingJP2025075148AOrganic active ingredientsHormone peptidesBULK ACTIVE INGREDIENTActive ingredient
To provide an adiponectin enhancer and an oral composition for enhancing adiponectin, having the effect of enhancing adiponectin.SOLUTION: An adiponectin enhancer comprises plasmalogen as an active ingredient.SELECTED DRAWING: Figure 1
Owner:INST OF RHEOLOGICAL FUNCTION OF FOOD
Dosage forms for Tyk2 inhibitors
Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.
Owner:BRISTOL MYERS SQUIBB CO
Methods for treating a fatty liver disease
The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.
Owner:MADRIGAL PHARMACEUTICALS INC
Application of Ackermann muciniphile in preparation of diabetic metabolic disease related renal injury products
The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.
Owner:THANKCOME BIOLOGICAL SCI & TECH CO LTD
Methods for weight management and mitigation of vesceral malaise
PCT designated stageWO2025171806A1Metabolism disorderPeptide/protein ingredientsAgonistWeight management
Owner:REZUBIO PHARM CO LTD
Devices and methods for collecting gastrointestinal samples
ActiveUS12349873B2Surgical needlesVaccination/ovulation diagnosticsBiomedical engineeringGastrointestines
Embodiments of devices and methods for collecting gastrointestinal samples using a capsule-shaped device that is swallowed are provided.
Owner:ENVIVO BIO INC
Inflammatory bowel disease model, construction method and application thereof, and drug evaluation method based on inflammatory bowel disease model
The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis
The present invention relates to pyridinyl derivatives of Formula (I) Formula (I) wherein R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.
Owner:IDORSIA PHARMACEUTICALS LTD
A Lactobacillus plantarum and its application in preparing a preparation for preventing and treating inflammatory bowel disease and having antioxidant, anti-inflammatory and antibacterial functions
The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.
Owner:SHANGHAI BONA TIANCHUN BIOTECHNOLOGY CO LTD
Inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof
PCT designated stage expiredWO2025089672A1Gastrointestinal cellsDrug screeningPharmacy medicineBowels diseases
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Owner:KOREA RES INST OF CHEM TECH +1
Akecman mucophilia and application thereof to prevention of non-alcoholic steatohepatitis
The invention relates to an Akecman mucophilic protein strain LWHK0003, which has the effects of preventing non-alcoholic steatohepatitis, resisting obesity, preventing NASH induced by GAN diet, maintaining constant blood sugar and resisting inflammation.
Owner:LEEUWENHOEK LABORATORIES CO LTD
Crystal form of tigorazan compound and preparation method and application thereof
The invention relates to a crystal form of a compound tigoran, a preparation method of the crystal form, a pharmaceutical composition containing the crystal form, and application of the crystal form in preparation of drugs for treating related diseases needing to control the pH value of gastric juice, such as gastroesophageal reflux disease and erosive esophagitis. The new crystal form DCVI of the compound tigorasone, provided by the invention, has an important value for the development of the medicine in the future.
Owner:BIRDO (SHANGHAI) PHARMATECH CO LTD
Desmopressin oral compositions
Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.
Owner:TULEX PHARMACEUTICALS INC
Bacterial biosensors for diagnosing and treating inflammation
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and / or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Owner:BAYLOR COLLEGE OF MEDICINE
Application of phenyllactic acid or composition containing phenyllactic acid in preparation of medicine for relieving lung diseases
The invention discloses an application of phenyllactic acid or a composition containing phenyllactic acid in preparation of medicines for relieving lung diseases, and in the application, the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, phenyllactic acid can effectively intervene in the inflammatory factor cascade reaction and oxidative stress injury process, and acute lung injury symptoms caused by the factors are remarkably improved. Compared with the traditional treatment means, the experiment proves that the phenyllactic acid or the composition containing the phenyllactic acid can obviously relieve the symptoms of acute lung injury (ALI) of mice induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of mice induced by bleomycin, the pathological change of the lung is effectively improved, and the lung function is recovered.
Owner:THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV
Orally administered corticosteroid compositions
The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
Owner:ELLODI PHARM LP
Self-driven micromotor system for treating helicobacter pylori gastritis and preparation method thereof
PendingCN120459060AAntibacterial agentsInorganic active ingredientsAntibacterial activityPharmaceutical Substances
The invention belongs to the technical field of biological medicines and micro-nano motors, and particularly relates to a self-driven micro-motor system for treating helicobacter pylori gastritis and a preparation method of the self-driven micro-motor system. A self-driven micro-motor system with an active targeting function is constructed, the drug coated on the PLGA layer can be any substance with antibacterial activity or capable of promoting gastric mucosa repair, and the drug loading capacity and the sustained release time can be adjusted by adjusting the thickness of the PLGA interlayer. The selection of the enteric coating layer mainly considers the good electrostatic targeting property and pH response release property of the enteric coating layer, and various types of enteric coatings can be selected to adjust pH nodes released by the shell.
Owner:SOUTHWEST JIAOTONG UNIV
Application of lanthanum carbonate in preparation of medicine for resisting liver cirrhosis and inhibiting liver inflammation
The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.
Owner:南昌大学第一附属医院
Application of SNHG8 in preparation of medicine for preventing and treating non-alcoholic fatty liver disease
ActiveCN120571022ADigestive systemNon-active genetic ingredientsPharmaceutical drugLiver triglyceride
The invention relates to the technical field of biotechnology and gene function and application, and provides application of SNHG8 in preparation of drugs for preventing and treating non-alcoholic fatty liver diseases. The medicine is used for preventing and treating the non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The SNHG8 is applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, the medicine can effectively reduce the content of triglyceride in the liver by promoting SNHG8 gene expression, liver lipid accumulation increase and lipid metabolism related protein expression up-regulation induced by high-fat and high-cholesterol diet are relieved, and therefore the non-alcoholic fatty liver disease is prevented, treated or relieved. The purpose of preventing and treating the non-alcoholic fatty liver disease is achieved.
Owner:南昌大学第一附属医院